Eddingpharm, GlaxoSmithKline sales and marketing update

GlaxoSmithKline granted Eddingpharm exclusive rights to market breast cancer drug Tykerb lapatinib in China. Tykerb is approved in China to treat advanced or metastatic HER2-positive breast cancer in combination with capecitabine in patients previously treated with an anthracycline, a taxane and trastuzumab. GSK markets lapatinib, a HER1 and HER2 receptor tyrosine kinase inhibitor, as Tykerb in the U.S. and as Tyverb in the EU. The partners could not be reached for details. ...